314 related articles for article (PubMed ID: 37460928)
21. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
[TBL] [Abstract][Full Text] [Related]
22. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
[TBL] [Abstract][Full Text] [Related]
23. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
Lee YJ; Kim D; Shim JE; Bae SJ; Jung YJ; Kim S; Lee H; Kim SH; Jo SB; Lee JY; Kim HS; Paik S
Int J Cancer; 2020 Apr; 146(7):1851-1861. PubMed ID: 31603993
[TBL] [Abstract][Full Text] [Related]
24. Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients.
Sugino K; Tamura R; Nakaoka H; Yachida N; Yamaguchi M; Mori Y; Yamawaki K; Suda K; Ishiguro T; Adachi S; Isobe M; Yamaguchi M; Kashima K; Motoyama T; Inoue I; Yoshihara K; Enomoto T
Sci Rep; 2019 Nov; 9(1):17808. PubMed ID: 31780705
[TBL] [Abstract][Full Text] [Related]
25. Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases.
Koczkowska M; Zuk M; Gorczynski A; Ratajska M; Lewandowska M; Biernat W; Limon J; Wasag B
Cancer Med; 2016 Jul; 5(7):1640-6. PubMed ID: 27167707
[TBL] [Abstract][Full Text] [Related]
26. Genomic Determinants of Homologous Recombination Deficiency across Human Cancers.
Qing T; Wang X; Jun T; Ding L; Pusztai L; Huang KL
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572800
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of homologous recombination repair pathway genes mutation in ovarian cancers.
Yi Z; Chen M; Sun S; Yang C; Mei Z; Yang H; Xiang Q; Qiu H
Cancer Innov; 2022 Oct; 1(3):220-228. PubMed ID: 38089758
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
[TBL] [Abstract][Full Text] [Related]
29. Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.
Holý P; Hlaváč V; Šeborová K; Šůsová S; Tesařová T; Rob L; Hruda M; Bouda J; Bartáková A; Mrhalová M; Kopečková K; Al Obeed Allah M; Špaček J; Sedláková I; Souček P; Václavíková R
Int J Cancer; 2024 Jul; 155(1):104-116. PubMed ID: 38447012
[TBL] [Abstract][Full Text] [Related]
30. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
31. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
32. Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.
Garsed DW; Alsop K; Fereday S; Emmanuel C; Kennedy CJ; Etemadmoghadam D; Gao B; Gebski V; Garès V; Christie EL; Wouters MCA; Milne K; George J; Patch AM; Li J; Arnau GM; Semple T; Gadipally SR; Chiew YE; Hendley J; Mikeska T; Zapparoli GV; Amarasinghe K; Grimmond SM; Pearson JV; Waddell N; Hung J; Stewart CJR; Sharma R; Allan PE; Rambau PF; McNally O; Mileshkin L; Hamilton A; Ananda S; Grossi M; Cohen PA; Leung YC; Rome RM; Beale P; Blomfield P; Friedlander M; Brand A; Dobrovic A; Köbel M; Harnett P; Nelson BH; Bowtell DDL; deFazio A;
Clin Cancer Res; 2018 Feb; 24(3):569-580. PubMed ID: 29061645
[No Abstract] [Full Text] [Related]
33. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
Truong H; Breen K; Nandakumar S; Sjoberg DD; Kemel Y; Mehta N; Lenis AT; Reisz PA; Carruthers J; Benfante N; Joseph V; Khurram A; Gopalan A; Fine SW; Reuter VE; Vickers AJ; Birsoy O; Liu Y; Walsh M; Latham A; Mandelker D; Stadler ZK; Pietzak E; Ehdaie B; Touijer KA; Laudone VP; Slovin SF; Autio KA; Danila DC; Rathkopf DE; Eastham JA; Chen Y; Morris MJ; Offit K; Solit DB; Scher HI; Abida W; Robson ME; Carlo MI
Eur Urol; 2023 Jan; 83(1):29-38. PubMed ID: 36115772
[TBL] [Abstract][Full Text] [Related]
34. Identification of mutations in the PI3K-AKT-mTOR signalling pathway in patients with macrocephaly and developmental delay and/or autism.
Yeung KS; Tso WWY; Ip JJK; Mak CCY; Leung GKC; Tsang MHY; Ying D; Pei SLC; Lee SL; Yang W; Chung BH
Mol Autism; 2017; 8():66. PubMed ID: 29296277
[TBL] [Abstract][Full Text] [Related]
35. Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma.
Goebel EA; Kerkhof J; Dzyubak O; McLachlin CM; McGee J; Sadikovic B
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011309
[TBL] [Abstract][Full Text] [Related]
36. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
McAlpine JN; Porter H; Köbel M; Nelson BH; Prentice LM; Kalloger SE; Senz J; Milne K; Ding J; Shah SP; Huntsman DG; Gilks CB
Mod Pathol; 2012 May; 25(5):740-50. PubMed ID: 22282309
[TBL] [Abstract][Full Text] [Related]
37. γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
Li Y; Wu T; Wang Y; Yang L; Hu C; Chen L; Wu S
Gynecol Oncol; 2018 Apr; 149(1):163-172. PubMed ID: 29429592
[TBL] [Abstract][Full Text] [Related]
38. Precision Oncology of High-Grade Ovarian Cancer Defined through Targeted Sequencing.
Wessman S; Fuentes BB; Törngren T; Kvist A; Kokaraki G; Menkens H; Hjerpe E; Hugo Y; Petta TB; Borg Å; Carlson JW
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680387
[TBL] [Abstract][Full Text] [Related]
39. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
[TBL] [Abstract][Full Text] [Related]
40. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR
Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]